• Period 2 study design and style centered on prosperous Stage 1/2 demo which include use of Tinnitus Useful Index (TFI) responder investigation for key efficacy endpoint
  • Client enrollment requirements refined to enrich examine populace
  • Best-line effects predicted in mid-2022

SAN DIEGO, March 25, 2021 (Globe NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical corporation committed to the enhancement of modern therapeutics for neurotology, nowadays introduced the initiation of a Section 2 clinical trial of OTO-313 in sufferers with unilateral tinnitus. The randomized, double-blind, placebo-managed Stage 2 study will enroll somewhere around 140 patients with persistent, early onset tinnitus of at the very least moderate severity. Next the profitable Period 1/2 trial, the main efficacy endpoint will be a responder evaluation based mostly on the proportion of people reporting a clinically meaningful enhancement in TFI from baseline to both Month 1 and Month 2 subsequent remedy. Best-line success are expected in mid-2022.

“Tinnitus is a widespread trouble that negatively impacts hundreds of thousands of people today by disrupting their skill to slumber, focus at function, and get pleasure from leisure routines. This often qualified prospects to stress and melancholy that can be very significant, as sadly reported in a new circumstance of a prominent post-COVID affected person experiencing unrelenting tinnitus,” reported David A. Weber, Ph.D., president and CEO of Otonomy. “Unfortunately, there are no approved drug treatment options for tinnitus and present remedy focuses on coping and masking mechanisms. OTO-313 was designed to deal with the underlying pathology developing the wrong notion of seem, with the Stage 1/2 trial demonstrating a clinically meaningful reduction in tinnitus severity in a group of responders. We are enthusiastic to be initiating the demo and advancing the OTO-313 application for this crucial unmet have to have.”

The Stage 2 demo will be performed at roughly 50 medical web sites in the U.S. and Europe. Next a guide-in period, people will be randomized to a solitary intratympanic injection of OTO-313 or placebo and then followed for 4 months. Regular with the Period 1/2 trial effects, the most important endpoint will be a responder evaluation dependent on the reduction in TFI rating from baseline to each Month 1 and Thirty day period 2 adhering to procedure. In buy to assess toughness of the treatment advantage, patients will be adopted for an further two months. Other actions of efficacy incorporate tinnitus loudness, tinnitus annoyance, and individual world effect of modify.

About Tinnitus

Tinnitus is the health care phrase for the perception of noise when there is no seem. It is usually described as a ringing in the ear but can also seem like roaring, clicking, hissing or buzzing. Tinnitus is typically brought about by cochlear harm thanks to abnormal noise, bodily trauma, persistent ear infection or exposure to an ototoxic agent, major to about-activation of auditory nerve fibers and the perception of sounds in the absence of an external stimulus. Roughly 10 percent of U.S. grownups experience from the issue, which can seriously impression daily functions and consequence in stress and anxiety and despair. Tinnitus also accounts for the most prevalent company-connected incapacity between veterans with an approximated cost exceeding $2 billion. There are at present no Food and drug administration approved drug treatment options for tinnitus.

About OTO-313

OTO-313 is a sustained-publicity formulation of the powerful and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. We believe that that gacyclidine can minimize the severity of tinnitus symptoms subsequent cochlear injuries by reducing the over-activation of ruined auditory nerve fibers in the cochlea and their connections. OTO-313 makes use of a novel, patent-shielded formulation technological know-how to offer many months of gacyclidine drug exposure in the internal ear subsequent a single intratympanic injection. In 2020, we described constructive benefits from a Section 1/2 demo of OTO-313 in people with unilateral tinnitus of at the very least moderate severity. This demo shown a positive medical reaction for OTO-313 using the Tinnitus Purposeful Index (TFI) that was correlated with advancements in tinnitus loudness, tinnitus annoyance and individual global impact of transform actions.

About Otonomy

Otonomy is a biopharmaceutical enterprise committed to the progress of revolutionary therapeutics for neurotology. The firm pioneered the application of drug delivery know-how to the ear in purchase to develop goods that realize sustained drug publicity from a solitary area administration. This solution is included by a wide patent estate and is becoming used to build a pipeline of solutions addressing crucial unmet health-related requires which includes Ménière’s illness, listening to loss, and tinnitus. For additional data make sure you take a look at www.otonomy.com.

Cautionary Take note With regards to Ahead On the lookout Statements

This press release consists of ahead-searching statements inside of the which means of the Personal Securities Litigation Reform Act of 1995. Forward-searching statements frequently relate to upcoming gatherings or the upcoming economic or working efficiency of Otonomy. Forward-searching statements in this press release include things like, but are not constrained to, statements similar to plans and anticipations relating to OTO-313, like with regard to client populations and the Phase 2 demo of OTO-313 expected timing of topline success of the Section 2 scientific trial of OTO-313 and statements by Otonomy’s president and CEO.

Otonomy’s anticipations pertaining to these issues may perhaps not materialize, and genuine final results in upcoming durations are subject to risks and uncertainties. Real results may possibly vary materially from individuals indicated by these forward-hunting statements as a final result of these pitfalls and uncertainties, which include but not restricted to: delays and disruption resulting from the COVID-19 pandemic and governmental and web site responses to the pandemic, together with current and upcoming impacts to Otonomy’s functions, the producing of its item candidates, the progression of its latest medical trials, and affected individual conduct and compliance Otonomy’s capability to precisely forecast financial success Otonomy’s capability to receive supplemental financing Otonomy’s dependence on the regulatory achievements and improvement of its products candidates the uncertainties inherent in the scientific drug advancement approach, like, devoid of limitation, Otonomy’s ability to adequately demonstrate the basic safety and efficacy of its products candidates, the nonclinical and scientific outcomes for its product candidates, which could not assist even more development, and problems connected to individual enrollment, carry out and compliance in clinical trials the integrity of affected individual-documented results in its present-day and long run scientific trials the threats of the occurrence of any party, change or other circumstance that could effects the efficiency under or give increase to the termination of Otonomy’s collaboration, co-promotion or license agreements, or that could effect Otonomy’s means to repay or comply with the conditions of the loan delivered by Oxford Finance LLC facet effects or adverse activities linked with Otonomy’s product or service candidates level of competition in the biopharmaceutical industry Otonomy’s dependence on third functions to conduct nonclinical scientific studies and scientific trials, and for the manufacture of its products candidates Otonomy’s capacity to defend its mental house in the United States and during the world and to assure compliance with numerous guidelines and restrictions in international locations in which it conducts clinical trials expectations relating to opportunity remedy gains, sector sizing, possibility and expansion Otonomy’s means to control functioning fees implementation of Otonomy’s business product and strategic ideas for its organization, products and technological innovation basic financial and market conditions and other pitfalls. Information relating to the foregoing and further pitfalls may possibly be uncovered in the portion entitled “Risk Factors” in Otonomy’s Yearly Report on Kind 10-K filed with the Securities and Trade Fee (SEC) on February 11, 2021, and Otonomy’s future reviews to be submitted with the SEC. The ahead-searching statements in this push launch are dependent on information and facts readily available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any ahead-on the lookout statements, besides as necessary by regulation.


Media Inquiries
Spectrum Science
Chloé-Anne Ramsey
Vice President
[email protected]

Investor Inquiries
Westwicke ICR
Robert H. Uhl
Taking care of Director
[email protected]